ONCAlert | Upfront Therapy for mRCC
EGFR+ Lung Cancer: Videos
Osimertinib Improves Survival in EGFR+ NSCLC, Poses New Challenges for Resistance
1:00 PM, Fri September 13, 2019
.jpg "Research Investigates Role of Antiangiogenic Agents and Checkpoint Inhibitors in EGFR NSCLC")
Research Investigates Role of Antiangiogenic Agents and Checkpoint Inhibitors in EGFR NSCLC
8:33 PM, Mon August 12, 2019
.jpg "Ramucirumab Used to Delay Relapse Following EGFR TKIs in EGFR+ NSCLC")
Ramucirumab Used to Delay Relapse Following EGFR TKIs in EGFR+ NSCLC
5:01 PM, Fri July 12, 2019
Interpreting the Role of the Ramucirumab Plus Erlotinib Combination in EGFR+ NSCLC
6:30 PM, Tue June 18, 2019
Comparing Results for 80 mg versus 160 mg Osimertinib in Advanced EGFR+ NSCLC
4:41 PM, Thu May 16, 2019
Investigating Osimertinib for Brain Activity in EGFR-Mutated Lung Cancer
8:52 PM, Tue April 16, 2019
Dr. Padda Explains the Current Role of Immunotherapy in EGFR-Mutant Lung Cancer
4:05 PM, Tue March 26, 2019
Examining Data for Osimertinib in EGFR+ Lung Cancer
5:56 PM, Fri January 25, 2019
